Search research articles
Contact Us
Filters
Showing results (21-30 of 29) with videos related to
Page
of 3
Sort By:
You have reached the last page of results.
This site can display upto 29 results.
Tidsskrift for Den Norske Laegeforening : Tidsskrift for Praktisk Medicin, Ny Raekke
|
September 10, 1996
[High-dose therapy of cancer with CD34 positive cells as stem cell support]
G Kvalheim, A Pharo, H Holte, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
June 24, 1998
Dosage of adjuvant G-CSF (filgrastim)-supported FEC polychemotherapy based on equivalent haematological toxicity in high-risk breast cancer patients. Scandinavian Breast Group, Study SBG 9401
J Bergh, T Wiklund, B Erikstein, et al.
Breast Cancer Research and Treatment
|
September 20, 2001
Effects of dose-intensive chemotherapy and radiotherapy on serum n-terminal proatrial natriuretic peptide in high-risk breast cancer patients
K S Hall, T Wiklund, B Erikstein, et al.
Cancer Research
|
June 26, 1999
CYP17 and breast cancer risk: the polymorphism in the 5' flanking area of the gene does not influence binding to Sp-1
V Nedelcheva Kristensen, E K Haraldsen, K B Anderson, et al.
Oncogene
|
March 14, 2000
Genetic variants of CYP19 (aromatase) and breast cancer risk
V N Kristensen, N Harada, N Yoshimura, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 15, 2002
Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment
A Howell, J F R Robertson, J Quaresma Albano, et al.
Oncogene
|
August 8, 2012
Flotillins as regulators of ErbB2 levels in breast cancer
S Pust, T I Klokk, N Musa, et al.
Lancet (London, England)
|
October 29, 2000
Tailored fluorouracil, epirubicin, and cyclophosphamide compared with marrow-supported high-dose chemotherapy as adjuvant treatment for high-risk breast cancer: a randomised trial. Scandinavian Breast Group 9401 study
J Bergh, T Wiklund, B Erikstein, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 16, 2007
Long-term follow-up of the SBG 9401 study comparing tailored FEC-based therapy versus marrow-supported high-dose therapy
N Wilking, E Lidbrink, T Wiklund, et al.
Page
of 3
Search research articles
Search
Showing results (21-30 of 29) with videos related to
Sort By:
Page
of 3
You have reached the last page of results.
This site can display upto 29 results.
Tidsskrift for Den Norske Laegeforening : Tidsskrift for Praktisk Medicin, Ny Raekke
|
September 10, 1996
[High-dose therapy of cancer with CD34 positive cells as stem cell support]
G Kvalheim, A Pharo, H Holte, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
June 24, 1998
Dosage of adjuvant G-CSF (filgrastim)-supported FEC polychemotherapy based on equivalent haematological toxicity in high-risk breast cancer patients. Scandinavian Breast Group, Study SBG 9401
J Bergh, T Wiklund, B Erikstein, et al.
Breast Cancer Research and Treatment
|
September 20, 2001
Effects of dose-intensive chemotherapy and radiotherapy on serum n-terminal proatrial natriuretic peptide in high-risk breast cancer patients
K S Hall, T Wiklund, B Erikstein, et al.
Cancer Research
|
June 26, 1999
CYP17 and breast cancer risk: the polymorphism in the 5' flanking area of the gene does not influence binding to Sp-1
V Nedelcheva Kristensen, E K Haraldsen, K B Anderson, et al.
Oncogene
|
March 14, 2000
Genetic variants of CYP19 (aromatase) and breast cancer risk
V N Kristensen, N Harada, N Yoshimura, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 15, 2002
Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment
A Howell, J F R Robertson, J Quaresma Albano, et al.
Oncogene
|
August 8, 2012
Flotillins as regulators of ErbB2 levels in breast cancer
S Pust, T I Klokk, N Musa, et al.
Lancet (London, England)
|
October 29, 2000
Tailored fluorouracil, epirubicin, and cyclophosphamide compared with marrow-supported high-dose chemotherapy as adjuvant treatment for high-risk breast cancer: a randomised trial. Scandinavian Breast Group 9401 study
J Bergh, T Wiklund, B Erikstein, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 16, 2007
Long-term follow-up of the SBG 9401 study comparing tailored FEC-based therapy versus marrow-supported high-dose therapy
N Wilking, E Lidbrink, T Wiklund, et al.
Page
of 3